Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Atara Biotherapeutics, Inc. - Common Stock
(NQ:
ATRA
)
8.080
-0.510 (-5.94%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atara Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
June 21, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
Via
Benzinga
Atara Biotherapeutics: Q4 Earnings Insights
March 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 17, 2024
Via
Benzinga
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
June 17, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
May 31, 2024
Via
Benzinga
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
May 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 20, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
ATRA stock results show that Atara Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 09, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 07, 2024
Via
Benzinga
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
April 08, 2024
Via
Benzinga
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023
March 28, 2024
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
March 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
March 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
March 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 06, 2024
Via
Benzinga
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
February 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
February 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
February 14, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
February 05, 2024
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 02, 2024
Via
Benzinga
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
January 31, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
January 15, 2024
Via
Benzinga
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.